Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
NDC 42385-928, Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate, tablet, film coated, from Laurus Labs Limited.
- Product NDC
- 42385-928
- Status
- Listed
- Labeler
- Laurus Labs Limited
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- ANDA
- Application
- ANDA212786
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/42385-928 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- EFAVIRENZ600 mg/1
- LAMIVUDINE300 mg/1
- TENOFOVIR DISOPROXIL FUMARATE300 mg/1
Pharmacologic classes
Cytochrome P450 2B6 Inducers [MoA]; Cytochrome P450 2C19 Inhibitors [MoA]; Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 3A Inducers [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Non-Nucleoside Analog [EXT]; Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]; Nucleoside Reverse Transcriptase Inhibitors [MoA]; Nucleoside Reverse Transcriptase Inhibitors [MoA]; Nucleosides [CS]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 42385-928-30 | 42385092830 | 30 TABLET, FILM COATED in 1 BOTTLE (42385-928-30) |
| 42385-928-90 | 42385092890 | 90 TABLET, FILM COATED in 1 BOTTLE (42385-928-90) |
Linked data
RxNorm, label and prices
RxNorm concepts
Related lookups
FDA label sections
GET /v1/drugs/labels/1f8f9fe1-b8fd-4f65-8832-9d3d6802d076
Use it
Look up 42385-928 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/42385-928 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 42385-928. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.